Cite
Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer
MLA
Zhengfang Yi, et al. “Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer.” EBioMedicine, vol. 31, May 2018, pp. 276–86. EBSCOhost, https://doi.org/10.1016/j.ebiom.2018.05.003.
APA
Zhengfang Yi, Xiaojun Ma, Yingqi Hua, Jingjie Li, Feifei Yang, Wangrui Jin, Zhengdong Cai, Wei Sun, Mingyao Liu, Yang Yang, Yihua Chen, Tao Zhang, Yuan He, & Lei Wang. (2018). Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer. EBioMedicine, 31, 276–286. https://doi.org/10.1016/j.ebiom.2018.05.003
Chicago
Zhengfang Yi, Xiaojun Ma, Yingqi Hua, Jingjie Li, Feifei Yang, Wangrui Jin, Zhengdong Cai, et al. 2018. “Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer.” EBioMedicine 31 (May): 276–86. doi:10.1016/j.ebiom.2018.05.003.